Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tissue factor pathway.

J H McVey1

  • 1Haemostasis Research Group, MRC Clinical Sciences Centre, Imperial College School of Medicine, London, UK.

Bailliere'S Best Practice & Research. Clinical Haematology
|June 17, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression and characterization of a codon-optimized blood coagulation factor VIII.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Factor VII promotes hepatocellular carcinoma progression through ERK-TSC signaling.

Cell death discovery·2016
Same author

Thrombalexins: Cell-Localized Inhibition of Thrombin and Its Effects in a Model of High-Risk Renal Transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Fibrocytes mediate intimal hyperplasia post-vascular injury and are regulated by two tissue factor-dependent mechanisms.

Journal of thrombosis and haemostasis : JTH·2013
Same author

Factor seven-activating protease: does it do what it says on the tin?

Journal of thrombosis and haemostasis : JTH·2012
Same author

In utero administration of Ad5 and AAV pseudotypes to the fetal brain leads to efficient, widespread and long-term gene expression.

Gene therapy·2011
Same journal

Preface

Bailliere's best practice & research. Clinical haematology·2000
Same journal

Index

Bailliere's best practice & research. Clinical haematology·2000
Same journal

Biotechnology: alternatives to human plasma-derived therapeutic proteins.

Bailliere's best practice & research. Clinical haematology·2000
Same journal

Red blood cell substitutes.

Bailliere's best practice & research. Clinical haematology·2000
Same journal

The risks of transfusion-transmitted infection: direct estimation and mathematical modelling.

Bailliere's best practice & research. Clinical haematology·2000
Same journal

Will genome detection replace serology in blood screening for microbial agents?

Bailliere's best practice & research. Clinical haematology·2000
See all related articles

Blood coagulation, essential for vascular integrity, begins with tissue factor (TF) activating factor VII (FVII). Tissue Factor Pathway Inhibitor (TFPI) then regulates this process to prevent excessive clotting.

Area of Science:

  • Biochemistry
  • Hematology
  • Molecular Biology

Background:

  • Blood coagulation preserves vascular integrity following injury.
  • Inflammatory mediators can initiate coagulation, leading to pathological fibrin deposition.
  • The coagulation cascade is a complex series of zymogen activations culminating in clot formation.

Purpose of the Study:

  • To elucidate the initiation and regulation mechanisms of the blood coagulation cascade.
  • To describe the role of Tissue Factor (TF) and Factor VII (FVII) in initiating coagulation.
  • To explain the inhibitory function of Tissue Factor Pathway Inhibitor (TFPI).

Main Methods:

  • The study describes the molecular interactions and activation steps within the coagulation cascade.
  • Focuses on the enzymatic activities and complex formations involved.

Related Experiment Videos

  • Explains the sequential activation of coagulation factors and regulatory feedback loops.

    • Main Results:

    • Coagulation initiation involves Tissue Factor (TF) binding and activating Factor VII (FVII) to Factor VIIa (FVIIa).
    • The TF-FVIIa complex amplifies coagulation by activating Factor IX (FIX) and Factor X (FX).
    • Tissue Factor Pathway Inhibitor (TFPI) inactivates the TF-FVIIa complex, forming a quaternary complex with FXa, thereby regulating clot formation.

    Conclusions:

    • The TF-FVIIa complex is crucial for initiating coagulation but is tightly regulated.
    • TFPI plays a vital role in preventing excessive coagulation by inhibiting the TF pathway.
    • Understanding these mechanisms is key to managing hemostasis and thrombotic disorders.